Antiangiogenic and antivascular therapy for cancer.
The great interest in the potential antineoplastic effect of targeting tumor-associated blood vessels has generated an expanding armamentarium of therapeutic tools that include antiangiogenic compounds, aimed at preventing the formation of vessels, and antivascular compounds, targeted to the existing tumor vasculature. Following promising preclinical studies, antiangiogenic drugs have rapidly gained access to clinical trials.
Taraboletti
G
G
Mario Negri Institute for Pharmacological Research, Bergamo, Italy. taraboletti@marionegri.it
Margosio
B
B
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001808:Blood Vessels / Q000187:drug effects*; D003131:Combined Modality Therapy; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D012039:Regional Blood Flow / Q000187:drug effects
D020533:Angiogenesis Inhibitors